Tosoh Bioscience, Inc.

Tosoh Bioscience, Inc., doing business as Tosoh USA, a foreign-owned for-profit manufacturer headquartered in Grove City, Ohio and South San Francisco, California, supplies hemoglobin A1C testing instrumentation, reagents, analyzers, and cost-per-reportable-result laboratory services to the Department of Veterans Affairs as a prime contractor on full-and-open procurements with no SBA set-asides. The company operates across 2,740 federal awards with $297.7 million in combined potential value, concentrated almost entirely within the VA's Veterans Integrated Service Networks, and competes exclusively without subcontractor involvement.

Tosoh's federal capability footprint centers on high-performance liquid chromatography (HPLC) diagnostic testing for diabetes management. The company manufactures ion exchange HPLC hemoglobin A1C analyzers, test cartridges, reagents, and consumables, and delivers these products through cost-per-reportable-result (CPRR) testing service agreements where the VA procures diagnostic results on a per-test basis rather than acquiring equipment outright. Representative work includes a $3.5 million Blanket Purchase Agreement with VISN 17 through April 2031 for A1C analyzer systems and testing services across multiple medical facilities; a $2.09 million BPA with VISN 16 through December 2030 for ion exchange HPLC A1C testing instrumentation and supplies; a $1.71 million BPA with VISN 6 through April 2030 for hemoglobin A1C testing products; and a $1.36 million Indefinite Delivery Contract with VISN 4 through March 2030 covering automated glycohemoglobin instrumentation and services across nine PA and DE medical centers. The company also holds a $3.5 million single-award IDIQ with VISN 22 for HbA1c analyzers and cost-per-test services, and smaller BPAs with VISN 2, VISN 5, VISN 9, VISN 10, VISN 15, VISN 21, and VISN 23.

Customer concentration is acute within the VA healthcare system. The top five VISNs account for 34 percent of awards by count but diverge significantly on dollars: VISN 12 leads with $129.2 million combined potential value across 146 awards, followed by VISN 15 with $35.5 million across 55 awards, while VISN 16 places third by dollar value at $16.5 million despite 296 awards—a pattern reflecting smaller average order sizes in the Eastern region. VISN 4 and VISN 17 round out the top five by dollars at $13.9 million and $12.5 million respectively. The top five customers represent 70 percent of combined potential value across the federal portfolio. One non-VA award appears: a $13,177 purchase order from the National Institute of Diabetes and Digestive and Kidney Diseases for a 9-tray sorter in August 2025.

Tosoh's vehicle position relies entirely on the GSA Schedule Critical Analyzers, Laboratory (FSS-66-III), from which 942 task orders carry $74.7 million in combined potential value. The company also places work under Federal Supply Schedule vehicles V797P7020A (974 task orders, $74.2 million) and V797P6566A (325 task orders, $6 million), with additional BPAs established directly under individual VISN procurement authority. Tosoh holds no seats on government-wide IDIQs, GWACs, or agency-wide contracts outside the VA system.

Activity trajectory shows stability over five years: 75 awards in 2022, declining to 55 in 2023, recovering to 62 in 2024, 61 in 2025, and 63 in 2026. This modest fluctuation masks the dollar concentration in high-value multi-year vehicles; the company was established as the sole-source supplier across most major VISN contracts, earning extended 5-year terms. Recompete risk is manageable: 52 awards worth $3.3 million combined potential value complete within the next twenty-four months, concentrated among routine annual renewals and option year exercises on standing BPAs rather than loss-of-contract scenarios.

Tosoh operates as a 100 percent prime contractor with no subcontractor relationships noted across the award portfolio. The company manufactures diagnostic equipment and delivers testing services directly; all identified federal work is performed by Tosoh as the provider of record. NAICS classification reflects analytical laboratory instrument manufacturing (1,111 awards), in-vitro diagnostic substance manufacturing (173 awards), and reference laboratory testing (526 awards by PSC). The procurement footprint is characterized by firm fixed-price task orders under standing BPAs, repetitive ordering against GSA Schedule vehicles, and sole-source awards reflecting the specialized nature of FDA-approved hemoglobin A1C analyzers and the established performance relationship with the VA system.